SPOTLIGHT -
Unmet Needs and Future Perspectives in Multiple Myeloma
A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.
Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma
An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.
MM: Managing Adverse Effects from Bispecific Antibodies
Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.
Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.
Treatment Options for Frontline and Relapsed Multiple Myeloma
An overview of multiple myeloma treatment options in the frontline and relapsed settings.
Patient Monitoring and Workup in Relapsed MM
Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.
Patient Profile 3: A 58-Year-Old with IgG Kappa Multiple Myeloma
Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.
Treatment Duration and Maintenance Therapy in NDMM
Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.
MAIA Trial: DRd in Patients with Newly Diagnosed MM
Insights gleaned from the MAIA trial, which researched daratumumab, lenalidomide, and dexamethasone in patients with newly diagnosed MM.
Patient Profile 2: A 74-Year-Old with Transplant-Ineligible NDMM
Myeloma experts present the case of a 74-year-old with transplant-ineligible newly diagnosed MM and offer their initial impressions.
Maintenance Therapy Regimens for Patients With Transplant-Eligible MM
An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.
Determining Transplant Eligibility in Newly Diagnosed MM
Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.
Triplet and Quadruplet Therapy Options for Patients With Transplant-Eligible NDMM
An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.
Patient Profile 1: A 61-Year-Old with Transplant-Eligible Newly Diagnosed MM
A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.
MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma
C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.
The Future of Immunotherapy is ‘Bright’ in Multiple Myeloma
C. Ola Landgren, MD, PhD, speaks about transplant eligibility, as well as new therapies and minimal residual disease negativity, in the multiple myeloma space.
An Examination of Modern Multidisciplinary Practices Vs ‘Old-School’ Cancer Care
C. Ola Landgren, MD, PhD, discusses the benefits obtained when patients have access to a full team of diverse caregivers rather than just a single physician.
Treatment Options and Unmet Needs Evaluated in Multiple Myeloma
C. Ola Landgren, MD, PhD, reviewed the plethora of emerging treatment options in multiple myeloma, and how unmet needs in the space can be overcome.
Management of Bispecific Toxicities and Final Thoughts on Treatments in MM
Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.
The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options
Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.
Rationale for Bispecific-Based Combinations in MM
Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.
Treatment Selection of Bispecifics in Relapsed-Refractory MM
Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.
Treatment Approaches for Patients with Relapsed-Refractory MM
Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).
Final Thoughts on Transplant-Ineligible Patients with MM
Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.
Review of Patient Subgroups in Transplant-Ineligible NDMM
Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.
Clinical Trials in Transplant-Ineligible NDMM
Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.
Induction Therapy in Transplant-Ineligible NDMM
A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.
Role of Transplant and Induction Therapies in NDMM
Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).
DETERMINATION, GRIFFIN, and MASTER Studies
Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.
Induction Regimen Options in Transplant-Eligible NDMM
Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.
